Greenwich LifeSciences Balance Sheet Health
Financial Health criteria checks 6/6
Greenwich LifeSciences has a total shareholder equity of $5.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $5.8M and $842.4K respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$5.82m |
| Equity | US$4.98m |
| Total liabilities | US$842.38k |
| Total assets | US$5.83m |
Recent financial health updates
We Think Greenwich LifeSciences (NASDAQ:GLSI) Can Afford To Drive Business Growth
Aug 22
Here's Why We're Not Too Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Situation
Jan 12We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate
Jan 29Recent updates
We Think Greenwich LifeSciences (NASDAQ:GLSI) Can Afford To Drive Business Growth
Aug 22Greenwich LifeSciences: Trying To Move A Needle That Doesn't Like To Budge
Jun 26Here's Why We're Not Too Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Situation
Jan 12We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate
Jan 29Greenwich LifeSciences: Persevering CEO And Interesting Data
Sep 06Greenwich LifeSciences halts stock buyback program
Jul 11Greenwich LifeSciences: A First Look
May 19Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential
Apr 21Companies Like Greenwich LifeSciences (NASDAQ:GLSI) Are In A Position To Invest In Growth
Feb 01We Think Greenwich LifeSciences (NASDAQ:GLSI) Can Afford To Drive Business Growth
Sep 30We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate
Apr 04Are Insiders Buying Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock?
Feb 16
What Is The Ownership Structure Like For Greenwich LifeSciences, Inc. (NASDAQ:GLSI)?
Dec 25Greenwich LifeSciences: Optimism On 'GP2' Breast Cancer Immunotherapy Candidate
Dec 23Greenwich LifeSciences under stress on pricing upsized $26.4M equity offering
Dec 18Greenwich LifeSciences inks deal with Westport Bio for pre-clinical coronavirus vaccine candidates
Dec 15Greenwich LifeSciences trebles in value as breast cancer therapy shines in mid-stage trial
Dec 09Financial Position Analysis
Short Term Liabilities: GLSI's short term assets ($5.8M) exceed its short term liabilities ($842.4K).
Long Term Liabilities: GLSI has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: GLSI is debt free.
Reducing Debt: GLSI currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GLSI has sufficient cash runway for 9 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: GLSI is forecast to have sufficient cash runway for 9 months based on free cash flow estimates, but has since raised additional capital.